PURPOSE: Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT) have motivated development of alternative, dose-intensive chemotherapeutic strategies as consolidation in primary CNS lymphoma (PCNSL). We performed a multicenter study of high-dose consolidation, without WBRT, in PCNSL. Objectives were to determine: one, rate of complete response (CR) after remission induction therapy with methotrexate, temozolomide, and rituximab (MT-R); two, feasibility of a two-step approach using high-dose consolidation with etoposide plus cytarabine (EA); three, progression-free survival (PFS); and four, correlation between clinical and molecular prognostic factors and outcome. PATIENTS AND METHODS: Forty-four patients with newly diagnosed PCNSL were treated with induction MT-R, and patients who achieved CR received EA consolidation. We performed a prospective analysis of molecular prognostic biomarkers in PCNSL in the setting of a clinical trial. RESULTS: The rate of CR to MT-R was 66%. The overall 2-year PFS was 0.57, with median follow-up of 4.9 years. The 2-year time to progression was 0.59, and for patients who completed consolidation, it was 0.77. Patients age > 60 years did as well as younger patients, and the most significant clinical prognostic variable was treatment delay. High BCL6 expression correlated with shorter survival. CONCLUSION: CALGB 50202 demonstrates for the first time to our knowledge that dose-intensive consolidation for PCNSL is feasible in the multicenter setting and yields rates of PFS and OS at least comparable to those of regimens involving WBRT. On the basis of these encouraging results, an intergroup study has been activated comparing EA consolidation with myeloablative chemotherapy in this randomized trial in PCNSL, in which neither arm involves WBRT.
RCT Entities:
PURPOSE: Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT) have motivated development of alternative, dose-intensive chemotherapeutic strategies as consolidation in primary CNS lymphoma (PCNSL). We performed a multicenter study of high-dose consolidation, without WBRT, in PCNSL. Objectives were to determine: one, rate of complete response (CR) after remission induction therapy with methotrexate, temozolomide, and rituximab (MT-R); two, feasibility of a two-step approach using high-dose consolidation with etoposide plus cytarabine (EA); three, progression-free survival (PFS); and four, correlation between clinical and molecular prognostic factors and outcome. PATIENTS AND METHODS: Forty-four patients with newly diagnosed PCNSL were treated with induction MT-R, and patients who achieved CR received EA consolidation. We performed a prospective analysis of molecular prognostic biomarkers in PCNSL in the setting of a clinical trial. RESULTS: The rate of CR to MT-R was 66%. The overall 2-year PFS was 0.57, with median follow-up of 4.9 years. The 2-year time to progression was 0.59, and for patients who completed consolidation, it was 0.77. Patients age > 60 years did as well as younger patients, and the most significant clinical prognostic variable was treatment delay. High BCL6 expression correlated with shorter survival. CONCLUSION: CALGB 50202 demonstrates for the first time to our knowledge that dose-intensive consolidation for PCNSL is feasible in the multicenter setting and yields rates of PFS and OS at least comparable to those of regimens involving WBRT. On the basis of these encouraging results, an intergroup study has been activated comparing EA consolidation with myeloablative chemotherapy in this randomized trial in PCNSL, in which neither arm involves WBRT.
Authors: Ulrich Herrlinger; Martin Schabet; Wolfram Brugger; Rolf-Dieter Kortmann; Wilhelm Küker; Martina Deckert; Corinna Engel; Hans-Jürgen Schmeck-Lindenau; Hans-Günther Mergenthaler; Peter Krauseneck; Christian Benöhr; Christoph Meisner; Otmar D Wiestler; Johannes Dichgans; Lothar Kanz; Michael Bamberg; Michael Weller Journal: Ann Neurol Date: 2002-02 Impact factor: 10.422
Authors: Chung-Che Chang; Bal Kampalath; Christopher Schultz; Ellen Bunyi-Teopengco; Brent Logan; Camellia Eshoa; Ayse P Dincer; Sherrie L Perkins Journal: Arch Pathol Lab Med Date: 2003-02 Impact factor: 5.534
Authors: M Montesinos-Rongen; R Küppers; D Schlüter; T Spieker; D Van Roost; C Schaller; G Reifenberger; O D Wiestler; M Deckert-Schlüter Journal: Am J Pathol Date: 1999-12 Impact factor: 4.307
Authors: Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: C Soussain; F Suzan; K Hoang-Xuan; N Cassoux; V Levy; N Azar; C Belanger; E Achour; V Ribrag; S Gerber; J Y Delattre; V Leblond Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Michael J Kluk; Bjoern Chapuy; Papiya Sinha; Alyssa Roy; Paola Dal Cin; Donna S Neuberg; Stefano Monti; Geraldine S Pinkus; Margaret A Shipp; Scott J Rodig Journal: PLoS One Date: 2012-04-12 Impact factor: 3.240
Authors: Haneen Shalabi; Anne Angiolillo; Gilbert Vezina; James L Rubenstein; Stefania Pittaluga; Mark Raffeld; Leigh Marcus Journal: Pediatr Hematol Oncol Date: 2015-09-18 Impact factor: 1.969
Authors: Neel K Gupta; Amber Nolan; Antonio Omuro; Erin G Reid; Chia-Ching Wang; Gabriel Mannis; Michael Jaglal; Julio C Chavez; Paul G Rubinstein; Ann Griffin; Donald I Abrams; Jimmy Hwang; Lawrence D Kaplan; Judith A Luce; Paul Volberding; Patrick A Treseler; James L Rubenstein Journal: Neuro Oncol Date: 2016-08-30 Impact factor: 12.300